Seer (SEER) Retained Earnings (2020 - 2026)
Seer (SEER) posted quarterly Retained Earnings of -$482.8 million for Q1 2026, down 17.1% year-over-year from -$582.4 million in Q1 2025, and down 105287.15% quarter-over-quarter from $459000.0 in Q4 2025.
Analysis
Seer (SEER) Retained Earnings (2020 - 2026) Analysis & Trends
Seer's Retained Earnings history runs 7 years deep, the most recent figure standing at -$482.8 million for Q1 2026.
- In Q1 2026, Retained Earnings fell 17.1% year-over-year to -$482.8 million; the TTM figure through Mar 2026 stood at -$482.8 million (down 17.1% YoY), while the FY2025 annual figure was $459000.0, up 237.5% from the prior year.
- Retained Earnings for Q1 2026 stood at -$482.8 million, down from $459000.0 in the prior quarter.
- The five-year high for Retained Earnings was $710.5 million in Q1 2024, with the low at -$482.8 million in Q1 2026.
- The 5-year median for Retained Earnings is -$243.5 million (2023), against an average of -$86.0 million.
- The sharpest annual moves came in 2022 and 2025: Retained Earnings jumped 989.78% in 2022, then slumped 158.03% in 2025.
- Seer's Retained Earnings stood at -$1.3 million in 2022, then surged by 84.65% to -$192000.0 in 2023, then jumped by 170.83% to $136000.0 in 2024, then jumped by 237.5% to $459000.0 in 2025, then sank by 105287.15% to -$482.8 million in 2026.
- Business Quant data shows SEER's Retained Earnings at -$482.8 million in Q1 2026, $459000.0 in Q4 2025, and -$450.0 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.10 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -4.00 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.05 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -6.33 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 4.38 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Seer | 107.57 Mn | 107.57 Mn | 1.51 Mn | 725.72 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 725.72 Mn |
| Mar 31, 2026 | 724.35 Mn |
| Dec 31, 2025 | 724.82 Mn |
| Sep 30, 2025 | 721.36 Mn |
| Jun 30, 2025 | 719.73 Mn |
| Mar 31, 2025 | 723.02 Mn |
| Dec 31, 2024 | 719.80 Mn |
| Sep 30, 2024 | 714.57 Mn |
| Jun 30, 2024 | 714.63 Mn |
| Mar 31, 2024 | 710.53 Mn |
| Dec 31, 2023 | 702.87 Mn |
| Sep 30, 2023 | 694.95 Mn |
| Jun 30, 2023 | 686.54 Mn |
| Mar 31, 2023 | 676.54 Mn |
| Dec 31, 2022 | 667.74 Mn |
| Sep 30, 2022 | 657.43 Mn |
| Jun 30, 2022 | 648.15 Mn |
| Mar 31, 2022 | 638.86 Mn |
| Dec 31, 2021 | 629.98 Mn |
| Sep 30, 2021 | 621.99 Mn |